Specialty Pharmacy Times: November/December

From the Chairman
Winds of Change Begin to Stir Specialty Pharmacy
In this issue of Specialty Pharmacy Times®, we highlight the goings-on at the National Association of Specialty Pharmacy Annual Meeting and Educational Conference along with some key trends to monitor closely in the year ahead.
Editorial
Looking Down the Road: Success and Access
If a specialty pharmacy wants to participate in providing products and services to patients, they must prepare.
Viewpoints: The Last Word
The Drug Pricing Debate Is Finally Shining a Light on Pharmacy Benefit Managers
There have been several recent federal efforts aimed at bringing more balance into the market by increasing PBM oversight.
In Practice
Just 2 CSTD Products Pass NIOSH’s 2015 Vapor Containment Performance Protocol
Health care providers should keep these results in mind when choosing a CSTD product to ensure that hazardous drugs are compounded and administered in the safest way possible.
Features
Health-System Specialty Pharmacies Becoming an Industry Cornerstone
A new trend is emerging as health system–based specialty pharmacies become a staple in the industry.
No Simple Answers for Lowering Drug Costs
Although there is a persistent need for lower prescription drug costs, this simple concept is complicated by multiple factors.
The Brave New World of 340B: Where Do We Go From Here?
It's been nearly a year since the new 340B payment rule implemented by the Centers for Medicare and Medicaid Services went into effect.
Responding Proactively to Antikickback Guidelines
The time has come to be proactive in finding a path that can benefit all potential stakeholders, rather than letting other third parties define the system in a way that negatively affects potential outcomes.
Health Care Economic Information and Its Impact on Value-Based Contracts
Payers and biopharmaceutical companies are increasingly interested in outcomes-based agreements in which payments for a treatment are based on how well it helps patients meet specific health outcomes.
Annual NASP Meeting Kicks Off With a Renewed Call for Advocacy
With change on the horizon in the health care sector, the 6th Annual National Association of Specialty Pharmacy (NASP) Meeting and Educational Conference returned with a strong message echoing the importance of advocacy on behalf of patients and the profession as a whole.
Oncology Pipeline Highlights: A Look at Current and Future Developments
With oncology agents now flooding the specialty drug pipeline, it is important to keep up with the latest developments and look ahead at innovative therapies on the horizon.
Former House Speaker Calls for Overhaul of Health Care System During NASP Keynote Speech
Those who do not get involved in health care reform efforts to make sure their voices are heard risk ceding important decisions to those who may lack the insight to make meaningful change.
CMS Update: Policy Initiatives Tackle Drug Pricing, Coverage Reform
In a session held at the National Association of Specialty Pharmacy Annual Meeting and Educational Conference, Kara E Cardinale, MPA, provided an update on regulatory actions in the health care space by the Centers for Medicare and Medicaid Services (CMS) and Department of Health and Human Services.
The Era of Specialty: An Update on Current Industry Trends
In a presentation held at the 2018 National Association of Specialty Pharmacy Annual Meeting and Educational Conference, Doug Long, MBA, provided insight into the growth of specialty, citing several areas to watch over the next few years.
Clinical Insights
Hemophilia Advancements and the Evolution of Patient Management
The coordinated-care models and high-touch services provided by specialty pharmacies put them in an ideal position to support patients with hemophilia now and in the future.
Takhzyro for Hereditary Angioedema
On August 23, 2018, the FDA approved lanadelumab-flyo (Takhzyro; Shire) for the prophylaxis treatment and prevention of hereditary angioedema (HAE) in patients 12 years or older.
Benralizumab for Severe Eosinophilic Asthma
Benralizumab (Fasenra) is indicated as an add-on therapy for patients with severe eosinophilic asthma.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$